MedMira Board Chairman Retires
“I have decided that the time is right for me to retire,” said Stephen Sham. “I have completed my role here and I am leaving MedMira in good
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Utilizing King’s proprietary technology, Embeda capsules contain extended-release morphine pellets, each with a sequestered core of naltrexone, an opioid antagonist. The formulation is designed to work such that